United Therapeutics (NASDAQ:UTHR) Director Christopher Causey Sells 1,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 1,000 shares of United Therapeutics stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $520.00, for a total value of $520,000.00. Following the transaction, the director owned 4,190 shares of the company’s stock, valued at $2,178,800. This represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Christopher Causey also recently made the following trade(s):

• On Tuesday, January 6th, Christopher Causey sold 1,000 shares of United Therapeutics stock. The shares were sold at an average price of $510.00, for a total value of $510,000.00.
• On Friday, January 2nd, Christopher Causey sold 1,000 shares of United Therapeutics stock. The shares were sold at an average price of $500.01, for a total value of $500,010.00.

United Therapeutics Price Performance

UTHR stock traded up $61.67 during midday trading on Wednesday, reaching $535.10. 1,042,334 shares of the company were exchanged, compared to its average volume of 347,023. The firm has a market capitalization of $23.04 billion, a price-to-earnings ratio of 20.28, a price-to-earnings-growth ratio of 2.53 and a beta of 0.85. The business has a 50-day moving average price of $484.23 and a two-hundred day moving average price of $443.45. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $537.19.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter last year, the company posted $6.19 EPS. United Therapeutics’s quarterly revenue was up 7.4% compared to the same quarter last year. As a group, analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and improving margins — UTHR reported $7.70 EPS vs. the $6.78 consensus and showed a healthy net margin (~40.7%), which supports near-term earnings credibility. United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates
• Positive Sentiment: Record full-year revenue — FY2025 revenue rose to $3.18B (up ~11% YoY), reinforcing longer-term growth trajectory beyond the quarter. United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Unusual options and high volume — Traders bought an elevated number of call contracts (4,930 calls, ~241% above average) and overall volume spiked, which can magnify intraday moves but is non-directional on fundamentals.
• Neutral Sentiment: Analyst stance mixed — Morgan Stanley reiterated a Hold with a $447 price target, signaling cautious near-term sentiment despite solid results. Balanced Hold on United Therapeutics Amid Near-Term Pressure and Key Late-Stage Pipeline Readouts
• Negative Sentiment: Revenue miss pressured the stock — Quarterly revenue of $790.2M came in below the ~$814.8M consensus, which was cited as the main reason for an early sell-off. United Therapeutics stock falls nearly 5% on revenue miss despite earnings beat
• Negative Sentiment: Sizable insider selling — COO Michael Benkowitz sold sizable blocks (multiple recent transactions totaling tens of thousands of shares), which can be interpreted negatively by some investors. United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 14,440 Shares

Institutional Trading of United Therapeutics

Large investors have recently made changes to their positions in the company. Torren Management LLC acquired a new position in United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC increased its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics during the 4th quarter worth $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on UTHR shares. UBS Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Tuesday, February 17th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research report on Wednesday, October 29th. Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. HC Wainwright upped their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Finally, Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.